# Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects

> **NCT01903824** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Cognitive Impairment

## Interventions

- **DRUG:** CEP-26401
- **DRUG:** donepezil hydrochloride
- **DRUG:** modafinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01903824
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903824, "Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01903824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*